5 Top Gainers In Healthcare Sector (QHC, MTP, SNSS...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Quorum Health Corporation (QHC)

Quorum Health is a provider of hospital and outpatient healthcare services in its markets across the United States.

Gained 22.31% to close Wednesday's (Apr.24) trading at $1.59.

News: No news

Recent events:

-- On April 15, 2019, the Company completed the sale of a 146-bed Scenic Mountain Medical Center in Big Springs, Texas. The total proceeds from the sale were approximately $22 million.

-- On March 12, 2019, the Company reported financial and operating results for the fourth quarter and year ended December 31, 2018.

Full-year net loss attributable to Quorum Health in 2018 was $200.2 million, or $6.91 per share on revenue of $1.88 billion. This compared with a net loss attributable to the Company of $114.2 million or $4.06 per share and revenue of $2.07 billion in 2017.

Looking ahead to 2019, the Company expects revenue to range between $1.83 billion to $1.88 billion.

2. Midatech Pharma Plc (MTP)

Midatech is a specialty pharmaceutical company, with a focus on products in oncology and immunotherapy in the United States and the United Kingdom.

Gained 14.22% to close Wednesday's trading at $2.57.

News: The Company announced financial results for the twelve-month period ended December 31, 2018.

Net loss from continuing operations narrowed to 10.37 million pounds in 2018 from 11.71 million pounds in 2017. Total gross revenue for 2018 from continuing operations jumped 96% to 1.94 million pounds from 0.99 million pounds in 2017.

Commenting on the full-year 2018 results, Midatech's Chief Executive Officer, Dr Craig Cook, said, "We believe the Company has entered a new chapter in its growth as a streamlined R&D focused business with in-house manufacturing. We are now delivering on clinical milestones, with strong clinical data, and a compelling pipeline for our proprietary drug delivery platforms, all of which are now into the clinic. We look forward to an exciting period ahead, creating value for all stakeholders."

3. Ra Medical Systems Inc. (RMED)

Ra Medical is a commercial-stage medical device company, with a focus on vascular and dermatological diseases.

The Company markets DABRA, a minimally-invasive excimer laser and disposable catheter system that is used as a tool in the endovascular treatment of vascular blockages, and Pharos Excimer Laser, a 308 nm ultraviolet-B excimer laser to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis, and leukoderma. Both the products are FDA cleared and CE Marked.

Gained 13.23% to close Wednesday's trading at $5.05.

News: No news

Recent event:

-- On March 14, 2019, the Company reported financial results for the three and 12 months ended December 31, 2018.

The net loss for the fourth quarter of 2018 widened to $14.9 million or $1.18 per share on net revenue of $2.0 million, which consisted of product sales of $1.2 million and service and other revenue of $0.8 million. This compared with a net loss for the fourth quarter of 2017 of $3.1 million, or $0.40 per share and net revenue of $1.9 million, comprised of product sales of $1.2 million and service and other revenue of $0.7 million.

Looking ahead, the Company expects net revenue of between $1.0 million and $1.4 million in the first quarter of 2019.

4. Sunesis Pharmaceuticals Inc. (SNSS)

Sunesis Pharma is focused on developing therapies for the treatment of solid and hematologic cancers.

Gained 13.08% to close Wednesday's trading at $1.47.

News: No news

Clinical Trials & Near-term Catalyst:

-- A phase 1b/2 trial of Vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies is ongoing. -- An update on the ongoing Vecabrutinib trial is expected to be provided at the European Hematology Association Congress (EHA) in June 2019.

5. ShockWave Medical Inc. (SWAV)

ShockWave Medical is a commercial-stage medical device company developing and marketing products based on intravascular lithotripsy (IVL) technology to treat calcified cardiovascular disease.

Gained 10.44% to close Wednesday's trading at $34.50.

News: No news

Recent event:

On March 7, 2019, the Company went public on the Nasdaq Global Select Market, offering its shares at a price of $17 each.

Near-term Catalyst:

The Company is slated to report financial results for the first quarter of 2019 after market close on Wednesday, May 8, 2019. This is its first earnings report as a public company.